MIPS 25th Anniversary Profile: A&G Pharmaceutical–Breast Cancer Theranostic Biomarker

Leading up to (and beyond) the Maryland Industrial Partnerships (MIPS) 25th Anniversary Gala, each weekday we will briefly profile one of the 500+ companies that have utilized MIPS funding to bring innovations to market and create jobs in Maryland. These profiles will be collected in a commemorative book, released at the celebration on November 7.

Project Manager:  Ginette Serrero, Ph.D.;  Principal InvestigatorKatherine Tkaczuk, M.D., UMB
Location:  Columbia, Maryland – Howard County;  Project Start Date:  8/1/2008

Business Description
A&G Pharmaceutical discovers, develops, and commercializes innovative personalized medicine products that improve the screening, monitoring, and targeted treatment of cancer and other human diseases. Ginette Serrero, CEO and co-founder of A&G, has discovered and patented (over 130  patents filed worldwide, >40 issued patents) its unique and novel biomarker, called GP88, and also known as progranulin. This protein is produced and required by cancer cells and enables them to proliferate and survive. GP88 is not produced by normal cells, thus GP88 is identified as a novel biomarker target for diagnostic and therapeutic product development. A&G is developing diagnostic tissue and serum test kits based on GP88 that will improve the early detection, diagnosis, and monitoring of breast cancer. One of the diagnostic products—a test kit validated for assessing GP88 in tumor biopsies—will also serve as a companion diagnostic to anti-GP88 immunotherapy. Both the tissue and serum tests have been validated at the University of Maryland Greenebaum Cancer Center and supported by grants from MIPS and the National Cancer Institute Small Business Innovation Research (SBIR) program.

Precision Antibody™, A&G’s wholly owned, highly automated service unit, generates revenue to fund the drug development effort by providing customized antibodies to leading pharmaceutical and biotechnology companies, as well as federal laboratories, and is recognized worldwide as a provider of high-quality, antibody-based products.

Ginette Serrero demonstrated that GP88 had the potential to be a biomarker for breast cancer, as increasing GP88 serum levels positively correlated with advancing disease. This initial observation  needed clinical validation in breast cancer patients.

Dr. Kate Tkaczuk, from the University of Maryland Greenebaum Cancer Center (GCC), performed a clinical study with newly diagnosed breast cancer patients stages 1 to 4. The two objectives of the study were to determine if: serum GP88 could be used to detect breast cancer by measuring GP88 serum and tissue levels at the time of diagnosis; and GP88 serum levels could be used to follow the therapy response and progression of the disease in stage 4 patients undergoing therapy. GP88 assays were conducted at A&G.

Correlations of GP88 serum levels with clinical parameters such as stage, therapy response and survival, established the clinical utility of the GP88 serum assay to detect the disease and to monitor response to therapy disease progression and recurrence in breast cancer patients.

In 2010, A&G Pharmaceutical received a $1.2 million Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) for the program “Novel Targeted Therapy for Breast Cancer,” focused on the development of a neutralizing therapeutic antibody against a novel cancer-associated protein, GP88. A&G has since raised $12 million in equity capital.

OncoStain 88 is currently in use as a tissue-based diagnostic test to predict the risk of recurrence in early stage breast cancer patients.

Dr. Ginette Serrero is a UMB professor who left her academic position to start A&G and commercialize her discovery of GP88. She is looking forward to the culmination of her work, which could result in a robust and accurate blood test for the early detection of breast cancer.

MIPS-Related Quotes
“I can see the benefits and the strengths of having Maryland companies working with University of Maryland faculty. The MIPS program was very useful and powerful in getting it [GP88] to the next level.”
– Dr. Ginette Serrero, CEO, A&G Pharmaceutical

“The MIPS program has been instrumental to the GP88 blood test. It’s helped the company tremendously.”
Michael Keefe, COO, A&G

Pictured, left to right: Jun Hayashi, Co-Founder and VP of Research & Development; Ginette Serrero, Co-Founder and CEO; and Michael Keefe, Chief Operating Officer, A&G Pharmaceutical.

Download the A&G Pharmaceutical spread from the upcoming book, “MIPS 25thAnniversary Commemorative Collection: Creating Partners in Innovation,” to released at the MIPS 25th Anniversary Gala on Nov. 7.

Leave a comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: